Quest Diagnostics director gets 72 shares via DRIP

Quest Diagnostics Inc. director Vicky B Gregg reported acquiring 72 shares of common stock on 2026-07-22 through a dividend reinvestment plan administered by the reporting person's broker.

Rhea-AI Filing Summary

Quest Diagnostics Inc. director Vicky B Gregg reported acquiring 72 shares of common stock on 2026-07-22 through a dividend reinvestment plan administered by the reporting person's broker. The shares were credited at $206.8080 per share, bringing the reported direct holdings to 18,386 shares. The disclosure notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but it was voluntarily reported earlier on Form 4.

Insider Trade Summary

Grant/Award: 72 shares

Grant/Award 1 txn

Insider Gregg Vicky B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	72	$206.808	$15K

Holdings After Transaction: Common Stock — 18,386 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 72.0000 shares Transaction price: $206.8080 per share Shares held after transaction: 18386.0000 shares

3 metrics

Shares acquired 72.0000 shares Common stock acquired on 2026-07-22 via dividend reinvestment plan

Transaction price $206.8080 per share Price per share for the 72 shares acquired through dividend reinvestment

Shares held after transaction 18386.0000 shares Total directly owned Quest Diagnostics common shares following the acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5

3 terms

dividend reinvestment plan financial

"shares that were acquired pursuant to a dividend reinvestment plan administered"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vicky B Gregg report for Quest Diagnostics (DGX)?

Vicky B Gregg reported acquiring 72 shares of Quest Diagnostics common stock on 2026-07-22. The shares were obtained through a broker-administered dividend reinvestment plan and were voluntarily reported early on Form 4, although eligible for deferred Form 5 reporting under Rule 16a-6.

How many Quest Diagnostics (DGX) shares does Vicky B Gregg hold after this Form 4?

After the reported transaction, Vicky B Gregg directly holds 18,386 shares of Quest Diagnostics common stock. This total reflects the addition of 72 shares acquired through the dividend reinvestment plan described in the Form 4 footnote.

At what price were the new Quest Diagnostics (DGX) shares credited in the dividend reinvestment?

The 72 Quest Diagnostics shares were credited at $206.8080 per share under the dividend reinvestment plan. This per-share figure is reported as the transaction price and applies to the shares acquired on 2026-07-22.

Was the Quest Diagnostics (DGX) Form 4 transaction made under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox was not selected, and the footnote instead describes a routine dividend reinvestment plan. The transaction reflects automatic reinvestment of dividends administered by the reporting person’s broker rather than a 10b5-1 trading plan.

Why was this Quest Diagnostics (DGX) dividend reinvestment reported on Form 4 instead of waiting for Form 5?

The dividend reinvestment was eligible for deferred reporting on Form 5 under Rule 16a-6. However, the reporting person chose to disclose the 72-share acquisition early on Form 4, as expressly stated in the footnote to the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:35 PM Accepted by SEC EDGAR 07/27/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gregg Vicky B

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		A	V	72(1)	A	$206.808	18,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Vicky B. Gregg	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)